Tag: Vocan
-
Core One Labs (COOL.C) takes their artificial psilocybin research to UBC
Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release. The collaboration gives Vocan access to a well-funded, world-class research facility and team to enhance their position in the nascent psychedelic medicine space, especially given the increasing…
-
Core One Labs (COOL.C) begins work on proprietary DMT production
Core One Labs’ (COOL.C) wholly-owned subsidiary Vocan Biotechnologies has initiated the design and engineering of a proprietary enzymatic production system for API-grade N,N-dimethyltryptamine, commonly known as DMT. DMT, also known as the “spirit molecule”, is a naturally occurring psychedelic and is an active component in ayahuasca. It plays an important role in various rites of…
-
Does Core One Labs (COOL.C) have a solution for psilocybin’s dosing problem?
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and addictions.
-
Core One Labs (COOL.C) acquires 100% of a synthetic psilocybin company
“This transaction will significantly enhance Core One Labs’ ability to innovate our psychedelic drug development program,” stated Joel Shacker, CEO of Core Labs.